IMMUNIC (IMUX) President and COO receives 253,000-share stock option grant

Rhea-AI Filing Summary

IMMUNIC, INC. reported that President and COO Jason Tardio received a grant of stock options covering 253,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The grant was conditionally approved by the board and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, aligning the executive’s compensation with longer-term company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tardio Jason

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	253,000	$0.00	--

Holdings After Transaction: Stock Option — 253,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Key Figures

Option grant size: 253,000 options Underlying shares: 253,000 shares Exercise price: $11.60 per share +4 more

7 metrics

Option grant size 253,000 options Stock options awarded to President and COO Jason Tardio

Underlying shares 253,000 shares Common stock underlying the reported stock options

Exercise price $11.60 per share Strike price for the stock option grant

Expiration date April 2, 2036 Option term end for the stock option grant

Initial vesting 25% on April 2, 2027 First vesting tranche of the option award

Remaining vesting period 36 monthly installments Remaining 75% vests in equal monthly increments

Holdings after grant 253,000 derivative securities Total options held directly after this transaction

Key Terms

Stock Option, 2019 Omnibus Equity Incentive Plan, Annual Meeting of Stockholders, vest

4 terms

Stock Option financial

"security_title: "Stock Option" and underlying_security_title: "Common Stock""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2019 Omnibus Equity Incentive Plan financial

"subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended"

Annual Meeting of Stockholders financial

"obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026"

vest financial

"The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:32 PM Accepted by SEC EDGAR 06/29/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardio Jason

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$11.6	06/29/2026		A		253,000(1)		(2)	04/02/2036	Common Stock	253,000	$0.00	253,000	D

Explanation of Responses:

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

2. The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

	/s/ Jason Tardio	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IMMUNIC (IMUX) President and COO Jason Tardio report in this Form 4 filing?

Jason Tardio reported receiving a grant of stock options for 253,000 shares of IMMUNIC common stock. These options are part of his equity compensation and give him the right to buy shares at a fixed exercise price over time.

What are the key terms of Jason Tardio’s IMMUNIC (IMUX) stock option grant?

The grant covers 253,000 underlying shares with an exercise price of $11.60 per share and an expiration date of April 2, 2036. This long-dated option award ties potential value to IMMUNIC’s future share performance.

How do Jason Tardio’s IMMUNIC (IMUX) stock options vest over time?

The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months. This schedule encourages long-term retention and alignment with IMMUNIC’s multi-year performance.

What shareholder approval was required for Jason Tardio’s IMMUNIC (IMUX) option grant?

The options were conditionally approved by the board, subject to stockholder approval of an amendment to IMMUNIC’s 2019 Omnibus Equity Incentive Plan. Stockholders approved this amendment at the 2026 Annual Meeting held on June 29, 2026.

Is Jason Tardio’s IMMUNIC (IMUX) Form 4 transaction a market purchase or sale of shares?

No. The Form 4 reports a grant of stock options as compensation, not an open-market purchase or sale. He acquired derivative securities giving the right to buy IMMUNIC shares later at a fixed exercise price.

How many IMMUNIC (IMUX) derivative securities does Jason Tardio hold after this option grant?

Following this transaction, Jason Tardio directly holds stock options covering 253,000 underlying shares of IMMUNIC common stock. This figure reflects the full size of the newly granted award reported in the Form 4.